Iterum Therapeutics plc
ITRM
$0.99
-$0.007-0.70%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 596.00K | 254.00K | -- | -- | -- |
| Gross Profit | -596.00K | -254.00K | -- | -- | -- |
| SG&A Expenses | 8.58M | 7.98M | 7.55M | 7.61M | 7.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.24M | 18.70M | 26.46M | 38.26M | 45.10M |
| Operating Income | -16.24M | -18.70M | -26.46M | -38.26M | -45.10M |
| Income Before Tax | -22.31M | -24.53M | -30.20M | -27.96M | -35.05M |
| Income Tax Expenses | 252.00K | 240.00K | 357.00K | 382.00K | 538.00K |
| Earnings from Continuing Operations | -22.56 | -24.77 | -30.55 | -28.34 | -35.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.56M | -24.77M | -30.55M | -28.34M | -35.58M |
| EBIT | -16.24M | -18.70M | -26.46M | -38.26M | -45.10M |
| EBITDA | -15.62M | -18.41M | -25.99M | -37.36M | -43.78M |
| EPS Basic | -1.00 | -1.31 | -2.00 | -2.00 | -2.64 |
| Normalized Basic EPS | -0.62 | -0.81 | -1.24 | -1.23 | -1.63 |
| EPS Diluted | -1.00 | -1.31 | -2.00 | -2.00 | -2.64 |
| Normalized Diluted EPS | -0.62 | -0.81 | -1.24 | -1.23 | -1.63 |
| Average Basic Shares Outstanding | 97.34M | 78.72M | 65.21M | 58.20M | 54.60M |
| Average Diluted Shares Outstanding | 97.34M | 78.72M | 65.21M | 58.20M | 54.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |